MIND CONTROL TECHNOLOGY
Dr Delgado’s 1950’S research
Dr Delgado’s implantable transponder – the “stimoceiver” used electrical stimulation to gain physical control, control of mood and behaviour through his radio-controlled implants. Several different areas of the brain were connected to electrodes. His work was tested on animals and humans…
Dr. José Delgado
Dr. José M.R. Delgado was a pioneering neurophysiologist at Yale known for his controversial research in the 1950s-70s on brain stimulation to control behaviour inventing devices like the “stimoceiver” for wireless brain implants.
Dr Delgado’s “stimoceiver” was famously used to stop a bull mid-charge, exploring neural roots of aggression, and laying groundwork for modern deep brain stimulation (DBS) therapies for psychiatric conditions, raising significant ethical questions about mind control and “psychocivilization”.
Professorship at Yale
Dr. Delgado was a professor of physiology and psychiatry at Yale University from 1950 onwards, where he conducted much of this ground breaking research.
Dr. Delgado was a visionary but polarizing figure who explored the physical control of the mind, creating devices and foundational knowledge that foreshadowed today’s brain-computer interfaces and neural therapies.
Key Aspects of His Research
Brain-Computer Interfaces (BCIs): Developed the stimoceiver, a wireless implant that could both record brain activity (EEG) and deliver electrical stimulation to specific brain regions, allowing remote control of behaviours in animals and some humans.
Behavioural Neuroscience: Conducted studies in cats, monkeys, and humans to map brain areas related to aggression, pleasure, memory, and social behaviour, finding points that could inhibit or induce feeding, aggression, and other actions.
The Famous Bull Experiment: Famously demonstrated his technology by stopping a charging bull in its tracks using stimulation delivered via an implanted stimoceiver, showcasing the potential for neurological control.
Ethical & Societal Implications
He envisioned using brain stimulation to create a “psychocivilized society” by controlling violent behaviour, sparking intense ethical debates that remain relevant today in discussions of neuroethics and “neurorights.”
Legacy
His work, though controversial, significantly influenced modern neuromodulation techniques, paving the way for treatments like deep brain stimulation (DBS) for epilepsy, depression, and Parkinson’s disease.
Read more at the Wiley Online and the Ovid Journal. Read more on Wikipedia
Written with Google AI
IMPLANTABLE
TRANSPONDER
Dr Delgado’s implantable transponder used electrical stimulation to gain physical control, control of mood and behaviour through his radio-controlled implants. Several different areas of the brain were connected to electrodes.
CONTEMPORY VIEW
OF DELGADO’S WORK
documentaries about
early research
BRITISH TECHNOLOGY &
AMERSHAM INTERNATIONAL
‘Amersham international manufactures biomedical devices and advanced imaging technology that allows accurate scanning of every area of the body through x-ray, ultrasound and nuclear imaging agents.’ This technology allows for accurate implanting of medical devices, including in the brain. Radio controlled brain implants have been in use since they were produced at Yale University in the 1950’s by Dr Delgado. It relies on a precise delivery system to implant them safely.
Amersham International is an example of British involvement in research technology. The company was established in 1946 as The Radiochemical Centre for government research. Margret Thatcher’s government sold it in the 1981 for a vastly reduced sum.
It was the first government privatisation and a public scandal followed. The company continued to acquire other bio technology businesses. It was bought in 2004 and is now owned by GE Healthcare, a division of General Electric. One of its subsidiaries now operates as Cytiva. www.cytivalifesciences.com
‘Amersham Health is an undisputed leader in the global diagnostic market and the top provider of x-ray, ultrasound, and nuclear imaging agents, the latter for use in spectroscopy and positron emission tomography (PET) scanning machines. Its radiotherapies-four brachytherapies or “seed” implants for cancer treatment and pain palliation-capture 50 percent of the worldwide radiotherapy market. Its MRI contrast agent Omniscan (gadodiamide) is second only to Schering AG’s Magnevist (gadopentate).’
https://www.pharmexec.com/
view/phenotype-genotype-amersham-health-paves-way
HOW TO FREE YOURSELF 